ONT-380 in Combination With Capecitabine and Trastuzumab in HER2-Positive Breast Cancer

June 15, 2015
Erika P. Hamilton, MD

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.